Risk factor
High price volatility
Profitability factor
Very low or no dividends
About
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E.
Target Price
The average target price of 0013.HK is 33 and suggests 60% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell